JTT-705. Japan Tobacco.
JTT-705 is a cholesteryl ester transfer protein inhibitor under development by Japan Tobacco Inc for the treatment of hyperlipidemia. The compound is undergoing phase I clinical trials in Japan and phase II clinical trials in Europe.
Linders
Joannes T
JT
Johnson & Johnson Pharmaceutical Research and Development, Department of Medicinal Chemistry, B-2340 Beerse, Belgium. jlinders@prdbe.jnj.com
D000577:Amides; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004952:Esters; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D013329:Structure-Activity Relationship; D013438:Sulfhydryl Compounds / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics
D000577:Amides; D004952:Esters; D000960:Hypolipidemic Agents; D013438:Sulfhydryl Compounds; C411602:dalcetrapib